Company profile
Eloxx Pharmaceuticals, Inc.
OTC: ELOX · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
29DFH 28DQ 37GM 3SS 58
v0.1 · 65/100 weight · provisional
↑ listing tenure, filing timeliness · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$6.0M
Employees
10
as of 2026-08-18
Market cap
$59.0M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$6.0M-$6.0M2025
Operating income-$6.4M-$6.4M2025
Total assets$5.3M$5.3M2025
Liabilities$17.2M$17.2M2025
Equity-$11.9M-$11.9M2025
Revenue trend
FY2012 – FY2025 · USD
FY12
FY12
FY14
FY14
FY25
FY25
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Eloxx Pharmaceuticals, Inc.’s revenue?
Eloxx Pharmaceuticals, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Annovis Bio, Inc.32DPliant Therapeutics, Inc.48DXBiotech Inc.47DEdesa Biotech, Inc.47DArch Biopartners Inc.13DInstil Bio, Inc.36DNeighbors
Middlesex →Key facts
CEOSumit Aggarwal
SectorHealthcare
IndustryBiotechnology
HeadquartersWatertown, MA
ExchangeOTC: ELOX
Employees10
IPO date1999-04-26
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.